CN Mobile Logo

Search form


Exjade Gains Approval in EU

Exjade Gains Approval in EU

BASEL, Switzerland—The European Commission (EC) has granted approval for Novartis' Exjade (deferasirox) to treat patients with transfusional iron overload in all 25 member states of the European Union (EU). Exjade, available in the United States, is an oral iron chelator that provides continuous chelation coverage with a single daily dose.

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.